Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN PHOSPHATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus CLINDAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN PHOSPHATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus CLINDAMYCIN.
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs Clindamycin
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin phosphate is a prodrug that is hydrolyzed to clindamycin, which reversibly binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking peptide bond formation. It exhibits primarily bacteriostatic activity against susceptible gram-positive cocci and anaerobes.
Inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome, blocking peptide bond formation.
Clindamycin 600-2700 mg/day IV divided every 6-8 hours. For severe infections, up to 4800 mg/day IV may be given.
150-450 mg orally every 6 hours; 600 mg to 1.2 g intravenously every 6-8 hours; maximum 4.8 g/day IV.
None Documented
None Documented
Clinical Note
moderateClindamycin + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Clindamycin."
Clinical Note
moderateClindamycin + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Clindamycin."
Clinical Note
moderateClindamycin + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Clindamycin."
Clinical Note
moderateClindamycin + Clotrimazole
The terminal elimination half-life is approximately 2.4-3.0 hours in adults with normal renal and hepatic function; prolonged to 3-6 hours in hepatic impairment and up to 8-14 hours in severe hepatic disease.
2.4 hours (range 1.5-5.1 hours) in adults with normal renal function; prolonged in severe hepatic impairment.
Clindamycin is primarily eliminated via hepatic metabolism; approximately 10% is excreted unchanged in urine, 3.6% in feces, and the remainder as inactive metabolites in bile and urine.
Approximately 10% of active drug and 90% as inactive metabolites via renal (feces 3.6% as active, bile significant for enterohepatic circulation).
Category C
Category A/B
Lincosamide Antibiotic
Lincosamide Antibiotic
"The metabolism of Clotrimazole can be decreased when combined with Clindamycin."